AARD · CIK 1774857
What Aardvark Therapeutics, Inc. told the SEC could break it.
Aardvark is a pre-revenue biotech whose fortunes ride on one lead candidate, ARD-101 — and that program just hit a setback. In February 2026 it voluntarily paused enrollment and dosing in its pivotal Phase 3 HERO trial after reversible cardiac observations in a healthy-volunteer study, putting its timeline and lead program at risk pending FDA discussions. That lands on a company with no product revenue, a widening net loss ($57.6 million in 2025 versus $20.6 million in 2024) and a $115.9 million accumulated deficit, leaving it dependent on equity financing to keep developing. Compounding it, it relies on third-party manufacturers — exposed to raw-material cost increases, trade-secret risk, and recent legislation that may restrict certain frequently China-based suppliers.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- Voluntary pause of Phase 3 HERO trial over cardiac observationsmedium
In February 2026 Aardvark voluntarily paused enrollment and dosing in its pivotal Phase 3 HERO trial (and OLE) for lead candidate ARD-101 after reversible cardiac observations in a healthy-volunteer study, putting its development timeline and lead program at risk pending FDA discussions.
“In February 2026, we voluntarily paused enrollment and dosing in the HERO trial based on reversible cardiac observations in a healthy volunteer study.”
SEC filing →As of 2026 - Reliance on third-party manufacturers for product candidatesmedium
Aardvark relies on third-party manufacturers (with risks including raw-material cost increases, trade-secret misappropriation, and termination/nonrenewal of agreements), and recent legislation may restrict certain frequently China-based third parties, exposing its supply chain.
“the possible misappropriation of our proprietary information, including our trade secrets and know-how; the possible increase in costs for the raw materials for our product candidates; and the possible termination or nonrenewal of any agreement by any third party at a time that is costly or inconvenient for us.”
Liquidity & debt
- Pre-revenue with widening losses and large accumulated deficitmedium
Aardvark has no product revenue, reported a $57.6M net loss in 2025 (vs $20.6M in 2024) and a $115.9M accumulated deficit, and expects continuing losses, leaving it dependent on equity financing to fund ARD-101 development.
“For the years ended December 31, 2025 and 2024, we reported a net loss of $57.6 million and $20.6 million, 41 respectively. As of December 31, 2025, we had an accumulated deficit of $115.9 million.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch